LHLukas Heinlein

Lukas Heinlein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lukas Heinlein has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Axel Hauschild

    Department of Dermatology, University Hospital (UKSH), Kiel, Germany

    2 shared publications
  • Bastian Schilling

    Department of Dermatology, Venereology and Allergology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany

    2 shared publications
  • Carola Berking

    Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany

    2 shared publications
  • Christoph Wies

    Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany

    2 shared publications
  • Dirk Schadendorf

    Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

    2 shared publications
  • Franz J. Hilke

    Department of Dermatology, Venereology and Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

    2 shared publications

Latest Publications

  • Top Cited Papers
    Open Access

    Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors

    by Sarah Haggenmüller, Christoph Wies, Julia Abels, Jana T. Winterstein, Lukas Heinlein, Carina Nogueira Garcia, Jochen S. Utikal, Sebastian A. Wohlfeil, Friedegund Meier, Sarah Hobelsberger, et al.

    Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792 melanoma-suspicious lesions prospectively collected at eight German hospitals. Moreover, we provide access to the largest panel-validated dataset featuring dermoscopic and histopathological images with metadata. Complete agreement is achieved in 53.5% of cases (424/792), and a majority vote ( ≥ five pathologists) in 90.9% (720/792). Considerable discordance is observed for non-invasive melanomas (complete agreement in only 10/73 cases). The expert panel disagrees with the local pathologists’ and dermatologists’ diagnoses in 14.9% and 33.5% of cases, respectively. This variability highlights the diagnostic challenges of early-stage melanomas and the need to reconsider how ground truth is established in routine care and AI research. Including at least two pathologists or virtual panels may contribute to more consistent diagnostic results.


  • Open Access

    Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care

    by Lukas Heinlein, Roman C. Maron, Achim Hekler, Sarah Haggenmüller, Christoph Wies, Jochen S. Utikal, Friedegund Meier, Sarah Hobelsberger, Frank F. Gellrich, Mildred Sergon, et al.

    Background: Early detection of melanoma, a potentially lethal type of skin cancer with high prevalence worldwide, improves patient prognosis. In retrospective studies, artificial intelligence (AI) has proven to be helpful for enhancing melanoma detection. However, there are few prospective studies confirming these promising results. Existing studies are limited by low sample sizes, too homogenous datasets, or lack of inclusion of rare melanoma subtypes, preventing a fair and thorough evaluation of AI and its generalizability, a crucial aspect for its application in the clinical setting. Methods: Therefore, we assessed “All Data are Ext” (ADAE), an established open-source ensemble algorithm for detecting melanomas, by comparing its diagnostic accuracy to that of dermatologists on a prospectively collected, external, heterogeneous test set comprising eight distinct hospitals, four different camera setups, rare melanoma subtypes, and special anatomical sites. We advanced the algorithm with real test-time augmentation (R-TTA, i.e., providing real photographs of lesions taken from multiple angles and averaging the predictions), and evaluated its generalization capabilities. Results: Overall, the AI shows higher balanced accuracy than dermatologists (0.798, 95% confidence interval (CI) 0.779–0.814 vs. 0.781, 95% CI 0.760–0.802; p = 4.0e−145), obtaining a higher sensitivity (0.921, 95% CI 0.900–0.942 vs. 0.734, 95% CI 0.701–0.770; p = 3.3e−165) at the cost of a lower specificity (0.673, 95% CI 0.641–0.702 vs. 0.828, 95% CI 0.804–0.852; p = 3.3e−165). Conclusion: As the algorithm exhibits a significant performance advantage on our heterogeneous dataset exclusively comprising melanoma-suspicious lesions, AI may offer the potential to support dermatologists, particularly in diagnosing challenging cases.